Company Overview - Nutriband Inc. is focused on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [4] - The AVERSA™ technology aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, particularly fentanyl [3][4] Preferred Stock Dividend - Nutriband is issuing a 25% preferred stock dividend, where shareholders of record on July 25, 2025, will receive one preferred share for every four common shares held [1] - The pay date for the new issuance is set for August 5, 2025 [1] Conversion and Dividend Details - Each preferred share will be convertible into one share of common stock upon FDA approval of the AVERSA Fentanyl product [2] - If not converted, preferred shares will receive an annual cash dividend from the company's profits, as determined by the Board of Directors [2]

Company Overview - Nutriband Inc. has been added to multiple Russell indexes, including the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 reconstitution [1][2] - The company focuses on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [6] Product and Technology - AVERSA™ technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly fentanyl [5] - The potential peak annual US sales for AVERSA Fentanyl are estimated to be between $80 million and $200 million [2] Market Context - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3] - FTSE Russell, the global index provider, emphasizes the importance of adapting indexes to reflect the evolving US economy, with a transition to semi-annual reconstitution planned for 2026 [4]